9DQA の概要
| エントリーDOI | 10.2210/pdb9dqa/pdb |
| 分子名称 | Retinoid isomerohydrolase, FE (II) ION, PALMITIC ACID, ... (5 entities in total) |
| 機能のキーワード | 7-bladed beta propeller, monotopic membrane protein, non-heme iron enzyme, retinoid isomerase, inhibitor, complex, hydrolase, isomerase, isomerase-inhibitor complex, isomerase/inhibitor |
| 由来する生物種 | Bos taurus (domestic cattle) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 123235.62 |
| 構造登録者 | |
| 主引用文献 | Bassetto, M.,Hu, Y.,Li, B.,Chen, X.,Saraswat, V.,Damacio, F.,Smidak, R.,Palczewski, K.,Tochtrop, G.P.,Kiser, P.D. Rationally Designed, Short-Acting RPE65 Inhibitors for Visual Cycle-Associated Retinopathies. J.Med.Chem., 68:17638-17652, 2025 Cited by PubMed Abstract: The visual cycle is a metabolic pathway essential for visual function. The bisretinoid byproducts of this pathway can induce retinal toxicity, as occurs in Stargardt disease type 1 (STGD1). Emixustat, which inhibits bisretinoid production, is a visual cycle modulator (VCM) that targets RPE65. However, it causes visual impairment due to its unfavorable duration of action. Here, we report ester-containing analogs of emixustat that are susceptible to hydrolytic clearance and function as short-acting VCMs. We show that the esterase-mediated metabolism of these compounds can be tuned while maintaining high-affinity RPE65 targeting. Compounds (EYE-002) and (EYE-003) containing diethyl acetate and valproate esters, respectively, allowed faster recovery of visual cycle function compared to emixustat. These molecules protected against retinal degeneration in mouse models of photic retinopathy and STGD1. These data demonstrate that shorter attenuation of the visual cycle can therapeutically intervene in retinal diseases with fewer visual side effects compared to emixustat. PubMed: 40764714DOI: 10.1021/acs.jmedchem.5c01353 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.1 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






